Evidence map›Paper›PMID 40491761›Full record

ArticleFrontiers in medicine2025

Tear IgE point-of-care testing for differentiating type I and type IV allergic conjunctivitis.

Xumin Shang, Yiqiu Zhang, Shunrong Luo, Miaomiao Liu, Hanqiao Li, Xie Fang, Zhiwen Xie, Xianwen Xiao, Zhengwei Yang, Yuan Lin and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xumin Shang *Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Yiqiu Zhang *Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Shunrong Luo *Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Miaomiao LiuXiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Hanqiao LiXiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Xie FangXiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Zhiwen XieXiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Xianwen XiaoXiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Zhengwei YangXiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Yuan LinXiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
Huping WuXiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to evaluate the diagnostic utility of point-of-care tear immunoglobulin E (IgE) testing in distinguishing between type I and type IV allergic conjunctivitis (AC), and to explore tailored treatment strategies. Methods: A total of 254 patients with perennial AC at Xiamen Eye Center were enrolled. Clinical data, including age, sex, symptoms, and signs, were collected. Tear total IgE was measured using the i-ImmunDx™ platform. Univariate and multivariate logistic regression analyses, along with ROC curve analysis, were used to assess the discriminative value of tear IgE and clinical parameters for AC subtypes. Results: The mean patient age was 14.11 ± 12.46 years; 182 were male. Mean conjunctivitis score was 4.09 ± 1.51, and mean tear IgE was 7.73 ± 16.76 IU/mL. Tear IgE levels negatively correlated with age ( Conclusion: Tear IgE effectively differentiates AC subtypes and correlates with disease severity. Patients with low IgE levels, indicative of type IV hypersensitivity, benefit from individualized anti-inflammatory therapies, supporting its role in personalized management.

Indexed as

allergic conjunctivitisconjunctivitis scoresIgEPOCTtear

Identifiers

PMID40491761
PMCPMC12146281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.